Imperial College London

DrPiersDaubeney

Faculty of MedicineNational Heart & Lung Institute

Professor of Practice (Paediatric Cardiology)
 
 
 
//

Contact

 

+44 (0)20 7351 8430p.daubeney

 
 
//

Location

 

Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Delle:2017:10.1007/s40256-017-0248-x,
author = {Delle, Donne G and Rosés, Noguer F and Till, J and Salukhe, T and Prasad, SK and Daubeney, PEF},
doi = {10.1007/s40256-017-0248-x},
journal = {Am J Cardiovasc Drugs},
title = {Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children.},
url = {http://dx.doi.org/10.1007/s40256-017-0248-x},
year = {2017}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - OBJECTIVE: Ivabradine is a selective and specific inhibitor of the I(f) current in the sinoatrial and atrioventricular nodes. It decreases heart rate and myocardial oxygen consumption at rest and during exercise. It is used in adults for management of heart failure and angina, but promising results have been obtained in postural orthostatic tachycardia syndrome (POTS). There is little experience of ivabradine in childhood, although it is used on a compassionate basis. Our aim was to review our experience of ivabradine in a retrospective evaluation of pediatric patients with POTS. METHODS: We evaluated all patients younger than 18 years for whom ivabradine had been prescribed for this indication, from February 2008 to June 2014. RESULTS: Twenty-two patients were identified (15 female). Median age was 14.5 years (11-17 years). The ivabradine dosage after up-titration was 0.1 mg/kg per dose twice daily. In 15 (68%) symptoms improved. Ivabradine was suspended in five, but only in one for worsening of symptoms. There was a reduction in heart rate on resting electrocardiogram (EKG) from a mean (standard deviation) of 82.5 (13.6) bpm to a mean of 71 (16.5) bpm (p = 0.007). No patient had increased duration of QTc (p = 0.44). One (4.5%) experienced phosphenes. CONCLUSIONS: From this initial experience, ivabradine is safe in patients younger than 18 years with POTS. We observed improvement of symptoms in 68% and phosphenes in less than 5%. Further studies are needed to assess the safety in a randomized control setting.
AU - Delle,Donne G
AU - Rosés,Noguer F
AU - Till,J
AU - Salukhe,T
AU - Prasad,SK
AU - Daubeney,PEF
DO - 10.1007/s40256-017-0248-x
PY - 2017///
TI - Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in Children.
T2 - Am J Cardiovasc Drugs
UR - http://dx.doi.org/10.1007/s40256-017-0248-x
UR - https://www.ncbi.nlm.nih.gov/pubmed/29027608
ER -